GlassScriptPhysician profile
Michael Andrew Schreck
NPI 1760475420
$1,530.10
in general payments reported to CMS, 2019-2025
19 companies · $441 in 2025
The $441 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $74.81 · 2021: $142 · 2022: $274 · 2023: $305 · 2024: $126 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $379.60 | 2020-2023 | Krystexxa |
| Smith+Nephew, INC. | $246.29 | 2019-2024 | Grafix, Stravix |
| Amgen INC. | $169.34 | 2024-2025 | Krystexxa |
| Pharming Healthcare, INC. | $123.84 | 2025 | Ruconest |
| Triad Life Sciences INC. | $107.86 | 2022 | |
| Zyla Life Sciences, INC. | $65.57 | 2019 | |
| Kerecis Limited | $61.71 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Nevro Corp. | $52.16 | 2022-2023 | Senza |
| Octapharma USA, INC. | $50.54 | 2025 | Panzyga |
| Kowa Pharmaceuticals America, INC. | $44.48 | 2023 | Seglentis |
| Polynovo North America LLC | $42.06 | 2023 | |
| Becton, Dickinson and Company | $38.15 | 2025 | Channel Drain |
| Ars Pharmaceuticals Operations, INC. | $29.36 | 2025 | Neffy |
| Ani Pharmaceuticals, INC. | $27.17 | 2025 | Purified Cortrophin Gel |
| Paratek Pharmaceuticals, INC. | $21.12 | 2024 | Nuzyra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arteriocyte Medical Systems, INC. | $20.65 | 2025 | Influx |
| Paragon 28, INC. | $19.70 | 2019 | |
| Integra Lifesciences Corporation | $18.96 | 2019 | |
| Amniox Medical, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schreck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.